Document:

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

INTELLECTUAL PROPERTY LICENSE AGREEMENT

 

THIS INTELLECTUAL PROPERTY LICENSE AGREEMENT
(the “Agreement”) is made and is effective as of the 3rd day of May, 2012 (hereinafter referred to as the
Effective Date) by and between Marina Biotech, Inc., a Delaware corporation, MDRNA Research, Inc., a Delaware corporation, and
Cequent Pharmaceuticals, Inc., a Delaware corporation, each having offices at 3830 Monte Villa Parkway, Bothell, WA, 98021 (hereinafter
collectively referred to as “MARINA”), and Monsanto Company, a corporation having a principal place of business at
800 North Lindbergh Boulevard, St. Louis, MO 63167 (hereinafter referred to as “MONSANTO” as defined herein). MARINA
and MONSANTO shall hereinafter be referred to collectively as “The Parties” and each, individually, as a “Party.”

 

RECITALS

 

WHEREAS, MARINA owns or controls certain
Intellectual Property (as defined herein) pertaining to nucleic acids;

 

WHEREAS, MONSANTO wishes to acquire and
MARINA is willing to grant to MONSANTO a perpetual, irrevocable, worldwide, exclusive license to use and otherwise exploit the
Intellectual Property in the Field (as defined herein), subject to the terms, provisions and conditions set forth in this Agreement;
and

 

WHEREAS, MARINA and MONSANTO are entering
into the Research Program (as defined herein) as part of this Agreement.

 

NOW, THEREFORE, in consideration of the
mutual covenants and obligations contained herein and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereto agree as follows:

 

NOW, THEREFORE, The Parties agree as follows:

 

1.          DEFINITIONS

 

1.1           “Affiliate”
shall mean any legal entity in which MONSANTO has (a) beneficial ownership of at least forty percent (40%) of the voting securities
of a corporation or other business organization with voting securities or (b) at least forty percent (40%) interest in the net
assets or profits of a partnership or other business organization without voting securities.

 

1.2           “Change
in Control” means (a) a transaction or series of related transactions following which persons who are the holders of voting
equity interests of MARINA as of the Effective Date of this Agreement no longer hold a majority of the outstanding voting equity
interests of MARINA on a fully diluted basis; or (b) occupation of a majority of the seats (other than vacant seats) on the board
of directors of MARINA by persons who were neither (i) nominated or approved by the board of directors of MARINA nor (ii) appointed
by directors so nominated.

 

    	 

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

 1.3           “Channel
Costs” means deductions actually incurred, allowed, paid, accrued or specifically allocated in financial statements in accordance
with GAAP, in preparing and utilizing distribution channels for a Product (including product returns, customer rebates, dealer
incentives, volume discounts, service fees, cash discounts, pre-pay discounts, local competitive response, transportation or cargo
insurance, etc.).

 

1.4           “Collateral”
means MARINA's rights under the Agreement and in all MARINA Intellectual Property licensed hereunder to MONSANTO which is subject
to the lien set forth in Article 15.1 of this Agreement.

 

1.5           “Cost
of Goods Sold” means, with respect to a Product of a Party, the costs incurred by or on behalf of such Party that are directly
attributable and reasonably allocable to the manufacturing and/or acquisition of such Product or components thereof, and supplying
of such Product, all in accordance with (as applicable to the selling Party) GAAP or IFRS, and specifically:

 

(a)    If the
Product is manufactured by such Party, the Cost of Goods Sold shall consist of the actual cost of manufacturing, including materials
costs, labor costs, and reasonable allocation of standard manufacturing overhead for the Product (processing, quality assurance
testing, filling, finishing, packaging labeling the Product; and a reasonable allocation of the production department’s utilities,
maintenance, engineering, safety, insurance, plant management (including plant human resources and finance), and depreciation of
capital equipment costs solely to the extent such capital equipment is used to manufacture such Products calculated in accordance
with generally accepted accounting principles consistently applied across such Party’s Products);

 

(b)   If the
Product or component of a Product is manufactured by a Third Party manufacturer, the Cost of Goods Sold shall consist of (i) such
Party’s actual cost of acquiring the Product or component from such Third Party manufacturer; plus (ii) such Party’s
cost of additional manufacturing, including materials costs, labor costs, and reasonable allocation of standard manufacturing overhead
as defined in Subsection (a) of this Article 1.5.

 

(c)   Cost of
Goods Sold does not include or encompass cost of abnormally destroyed or discarded Products.

 

1.6           “Effective
Date” has the meaning set forth in the Preamble of this Agreement.

 

1.7           “Field”
means [***].

 

1.8           “Gross
Profit” means Sales Revenue less (i) royalties paid to Third Parties in connection with Product provided (A) the royalties
are specifically allocated to the Product and are paid pursuant to a written agreement and (B) the amount of royalties deducted
in calculating Gross Profits shall not exceed four percent (4%) of Sales Revenue, (ii) Channel Costs and (iii) Cost of Goods
Sold.

 

    	2

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

1.9           “Improvement”
means any development, modification or enhancement made within one year of the Effective Date, whether or not patentable, and relating
to the MARINA Patent Rights or to the MARINA Technology as it existed on the Effective Date.

 

1.10         “Intellectual
Property” means any (A) trade secret, (B) invention, process, design, or plant protected under title 35 of the United States
Code as amended from time-to-time, (C) patent application, (D) plant variety, (E) work of authorship protected under title
17 of the United States Code as amended from time-to-time or (F) mask work protected under chapter 9 of title 17 of the United
States Code, as amended from time-to-time.

 

1.11         
“Joint Improvement” means any Improvement made jointly by (a) at least one employee of MARINA or another person under
contract with MARINA (which contract provides that all intellectual property rights in any such Improvement conceived or reduced
to practice by that person under such contract belong to MARINA) and (b) at least one employee of MONSANTO or another person under
contract with MONSANTO (which contract provides that all intellectual property rights in any such Improvement conceived or reduced
to practice by that person under such contract belong to MONSANTO).

 

1.12         
“Joint Patent Rights” means all U.S. and foreign patents and patent applications, including any reissues, extensions,
substitutions, continuations, divisions and continuations-in-part claiming, as an invention, any Joint Improvement.

 

1.13         “MARINA
Improvement” means any Improvement, other than a Joint Improvement, made by at least one employee of MARINA or another person
under contract with MARINA (which contract provides that all intellectual property rights in any such Improvement conceived or
reduced to practice by that person under such contract belong to MARINA); provided, however, that MARINA Improvements
shall not include any Improvement paid for by a Third Party pursuant to a written agreement between MARINA and such Third Party.

 

1.14         
“MARINA Patent Rights” means (i) all issued patents and patent applications listed on Schedule 1.14A to this
Agreement, (ii) all patent applications filed by MARINA within one (1) year of the Effective Date and all patents issuing therefrom
claiming a MARINA Improvement and (iii) any foreign patents and patent applications corresponding to the issued patents and patent
applications identified in clauses (i) and (ii) of this paragraph and (iv) any reissues, reexaminations, extensions, substitutions,
divisions, continuations, and continuations-in-part of any thereof. For the avoidance of doubt, MARINA Patent Rights shall not
include any of the patents or applications listed on Schedule 1.14B to this Agreement.

 

1.15         “MARINA
Technology” means all information embodied in a tangible medium, know how, processes, techniques, methods and data or other
Intellectual Property, including MARINA Improvements, and all MARINA data, back-up data, research, materials, files, contents of
files, formulations, drawings and sketches, designs, and testing and test results, whether patentable or not, which (i) is owned
or controlled by MARINA on the Effective Date or is developed by or on behalf of Marina within one (1) year of the Effective Date,
(ii) relates to nucleic acids, the MARINA Patent Rights, or Oligonucleotide Delivery Compositions and (iii) which MARINA has the
right to disclose and license to MONSANTO. For the avoidance of doubt, Marina Technology shall not include any Intellectual Property
or technology which is owned or controlled by Third Parties on the Effective Date and is acquired by or licensed to MARINA after
the Effective Date.

 

    	3

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

1.16         
“MONSANTO” means Monsanto Company and, in Monsanto Company’s sole discretion and where applicable, any of its
Affiliates.

 

1.17         “NVS
Agreement” means that certain agreement, dated as of March 20, 2009, by and between Novartis Institutes for BioMedical Research,
Inc., a Delaware corporation (“Novartis”), and Marina Biotech, Inc., a Delaware corporation (“Marina”;
formerly known as mdRNA, Inc.).

 

1.18         “Oligonucleotide
Delivery Composition” means any composition of matter that is complexed with an oligonucleotide composition (or
analog of an oligonucleotide composition) for the delivery
of such oligonucleotide composition (or analog of an oligonucleotide composition)
to a targeted medium, including, but not limited to a biological organism, tissue or cell.

 

1.19         
“Oligonucleotide Formulation Product” means an Oligonucleotide Delivery Composition the manufacture, use, or sale of
which would constitute, but for the license(s) granted MONSANTO pursuant to this Agreement, infringement of any issued, unexpired
claim within the MARINA Patent Rights.

 

1.20         
“Product” means an Oligonucleotide Formulation Product or a Special Product.

 

1.21         
“Research Deliverables” means the formulated oligonucleotide complexes that MARINA shall provide to MONSANTO, in accordance
with the terms and specifications of the Research Program.

 

1.22         “Research
Program” means the research plan outlined in Schedule 1.22 attached to this Agreement. In the event that MONSANTO
desires MARINA to conduct research in addition to or different from the research described in the Research Program, the parties
will negotiate in good faith regarding suitable charges, including FTE rates, and timetables for such additional research and,
if appropriate, may amend Schedule 1.22 from time-to-time to reflect the Parties’ agreement regarding such additional
or different research.

 

1.23         “Sales
Revenue” means:

 

(a)   Except
as otherwise provided in paragraphs (b) or (c) of this Article 1.23, actual amounts of revenues received by MONSANTO in bona fide
arms-length transactions for sale, license, lease or other transfer of a Product, provided, that Sales Revenue shall not
include any consideration received by MONSANTO for sales of any other product directly or indirectly included within the scope
of the transaction.

 

    	4

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

(b)   If
a Product offered, sold, licensed, leased or otherwise transferred as permitted under this Agreement comprises other component(s),
product(s), composition(s) or technology(ies) not covered by the MARINA Patent Rights nor constituting MARINA Technology, Sales
Revenue shall be determined by a method that equitably apportions the relative fair market value of the portion of the Product
covered by the MARINA Patent Rights or otherwise constituting MARINA TECHNOLOGY and the portion of the Product not covered by the
MARINA Patent Rights nor constituting MARINA Technology in a manner that is generally consistent with MONSANTO’s then-current
custom and practice. Such Sales Revenue shall not, however, exceed the sum of all amounts or revenues received for the MARINA Patent
Rights nor constituting MARINA Technology MARINA Intellectual Property in the same Product.

 

In the case of any sale of a Product for consideration other than cash, such as barter
or countertrade, Sales Revenue shall be calculated on the fair market value of the consideration received as reasonably agreed
by the Parties.

 

1.24         “Special
Product” means any article, composition of matter, combination, device or kit other than an Oligonucleotide Formulation Product
the manufacture, use, or sale of which would constitute, but for the license(s) granted MONSANTO pursuant to this Agreement, infringement
of any issued, unexpired claim within the MARINA Patent Rights.

 

1.25         “Territory”
means all countries of the world in which MARINA presently has, and in the future secures, intellectual property rights licensed
under this Agreement, subject only to any limitations expressly provided in this Agreement.

 

1.26         “Third
Party” means any person(s) or entity(ies) other than MARINA, MONSANTO and MONSANTO Affiliates.

 

2.          GRANT

 

2.1           Subject
to the limitations set forth in this Agreement and subject to the rights and licenses granted under the NVS Agreement and subject
to Article 2.6, MARINA hereby grants to MONSANTO and MONSANTO hereby accepts a perpetual, irrevocable, exclusive license, with
the full right to sublicense, under the MARINA Patent Rights to make, have made, use, import, export, sell, and have sold Products
in the Field and in the Territory during the term of this Agreement.

 

2.2           Subject
to the limitations set forth in this Agreement and subject to the rights and licenses granted under the NVS Agreement and subject
to Article 2.6, MARINA hereby grants to MONSANTO and MONSANTO hereby accepts a perpetual, irrevocable, exclusive license, with
the full right to sublicense, to use the MARINA Technology in the Field and in the Territory.

 

2.3           [***]

 

2.4           MONSANTO
hereby grants to MARINA and MARINA hereby accepts a perpetual, worldwide, irrevocable, royalty-free exclusive license, with the
full right to sublicense, under the Joint Improvements and the Joint Patent Rights to make, have made, use, import, export, sell,
and have sold products solely outside the Field and to otherwise exploit the Joint Improvements and Joint Patent Rights solely
outside the Field.

 

    	5

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

2.5           MARINA
will take all steps necessary to ensure that, within 120 days after the Effective Date, title to all of the MARINA Patent Rights
are vested in Marina Biotech, Inc. Upon delivery to MONSANTO of a revised copy of Schedule 1.14A reflecting the fact that all MARINA
Patent Rights are held in the name of Marina Biotech, Inc., which copy is certified by a duly authorized officer of Marina Biotech,
Inc., MONSANTO agrees to amend this Agreement so that MDRNA Research, Inc., and Cequent Pharmaceuticals, Inc. cease to be parties
hereto and are released from any and all obligations and liabilities hereunder.

 

2.6           Notwithstanding
the exclusive licenses extended in Articles 2.1 and 2.2, MARINA retains the right to license the manufacture and use of Unlocked
Nucleobase Analogs (UNA), Conformationally Restricted Nucelotides (CRN) and both CRN-substituted and UNA-modified oligonucleotides
as reagents and probes for research purposes outside of the Field. Such reagents and probes constitute: (1) oligonucleotide products
with or without modifications for research uses only containing one or more UNA-A, UNA-C, UNA-G, UNA-T or UNA-U monomers, and complexes
involving more than one oligonucleotide of which at least one contains one or more UNA-A, UNA-C, UNA-G, UNA-T or UNA-U monomers;
and (2) oligonucleotide products with or without modifications for research uses only containing one or more CRN-A, CRN-C,
CRN-G, CRN-T or CRN-U monomers, and complexes involving more than one oligonucleotide of which at least one contains one or more
CRN-A, CRN-C, CRN-G or CRN-U monomers. Research uses are scientific experimentation which may include experimentation which may
result in developing commercial products for therapeutic purposes, diagnostic purposes or other mammalian pharmaceutical purposes.
For the avoidance of doubt, MARINA’s right to license technology pursuant to this Article 2.6 does not comprise the right
to license the manufacture or use of Unlocked Nucleobase Analogs (UNA), Conformationally Restricted Nucelotides (CRN) and both
CRN-substituted and UNA-modified oligonucleotides as reagents and probes for non-research purposes in the Field.

 

3.          DELIVERY
OF MARINA TECHNOLOGY AND MARINA PATENT RIGHTS

 

3.1           The
MARINA TECHNOLOGY, as it exists as of the Effective Date, shall be made available to MONSANTO, including prompt delivery to MONSANTO.
MARINA shall notify MONSANTO of each Improvement and promptly deliver same to MONSANTO after it is first developed. Such notice
shall include a confidential written invention disclosure, in a form consistent with MARINA’s ordinary practice, describing
the relevant Improvement. To facilitate the prompt delivery and disclosure of such MARINA TECHNOLOGY and Improvements to MONSANTO,
MARINA shall provide MONSANTO with complete and unfettered access to MARINA’s property, plant, premises, data, back-up data,
research, materials, files, contents of files, formulations, drawings and sketches, designs, testing and test results relating
to such MARINA TECHNOLOGY and Improvements, and personnel having knowledge of such MARINA TECHNOLOGY and Improvements; provided,
however, that nothing herein shall be construed to obligate MARINA to afford MONSANTO with access to any information or technology
proprietary to any Third Party and subject to non-disclosure obligations prohibiting Marina from disclosing the same to MONSANTO.
Upon reasonable notice, MONSANTO shall obtain access to Marina and Marina personnel during ordinary business hours, and may copy
or otherwise reproduce any and all such data, back-up data, research, materials, files, contents of files, formulations, drawings
and sketches, designs, testing and test results and communicate with said personnel. MONSANTO personnel afforded access to MARINA’s
premises, equipment (including computer equipment) and personnel shall conduct themselves in a manner that (i) minimizes disruptions
to the conduct of MARINA’s business in the ordinary course, and (ii) is consistent with MARINA’s standards and policies
governing personnel, safety and security. All information obtained by MONSANTO pursuant to the Article 3.1 shall be considered
Confidential Information of MARINA.

 

    	6

    	 

    
 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

3.2           MARINA
shall update Schedule 1.14A to this Agreement, as necessary from time-to-time, to reflect all patent applications and issued patents
comprised by the MARINA Patent Rights and MARINA shall promptly deliver each updated version of Schedule 1.14A to MONSANTO.

 

3.3           MONSANTO
shall have six (6) months from the Effective Date to review Schedule 1.14B to identify patents and patent applications that are
relevant to the Field and to request that such patents or patent applications be included on Schedule 1.14A instead of Schedule
1.14B. Such request shall not be unreasonably denied. MONSANTO shall have the right at any time to request that any patent or patent
application appearing on Schedule 1.14A be included on Schedule 1.14B instead of Schedule 1.14A; effective with the date of such
request, MONSANTO shall thereafter have no further right or obligation under this Agreement with respect to the patent or patent
application that MONSANTO requests be included on Schedule 1.14B instead of Schedule 1.14A.

 

4.          PAYMENTS
& REPORTS

 

4.1           The
Parties recognize that the Intellectual Property licensed hereunder has never been used, adapted for use or commercialized in the
Field, and this Intellectual Property has been developed and applied only within the field of human and veterinary therapeutic
applications. As such, it is difficult to identify with precision the consideration to support this Agreement given the many uncertainties
associated with the complete lack of adaptation for agricultural purposes. Consequently, the parties acknowledge these uncertainties
and stipulate and agree that the consideration to be paid hereunder is fair given those circumstances and that the terms of this
Agreement are the result of arm’s length, good faith negotiations between the Parties.

 

4.2           In
partial consideration for the licenses, the Research Deliverables and other rights granted to MONSANTO hereunder, MONSANTO agrees
to pay to MARINA a single, one-time lump sum, non-refundable, non-creditable license initiation fee (hereinafter “License
Initiation Issue Fee”) in the amount of One Million Two Hundred Fifty Thousand Dollars ($1,250,000) within three (3) days
following the Effective Date of this Agreement.

 

4.3           Within
forty-five (45) days of MONSANTO’s receipt of the last of the Research Deliverables to be delivered to MONSANTO, MONSANTO
shall pay a non-refundable, non-creditable deferred license initiation fee in the amount of Two Hundred Fifty Thousand Dollars
($250,000) (hereinafter “Deferred License Initiation Fee”).

 

    	7

    	 

    
 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

4.4           MONSANTO
shall pay to MARINA a royalty of [***] percent ([***]%) of Gross Profits realized from sales of Oligonucleotide Formulation Product(s)
and a royalty of [***] percent ([***]%) of Gross Profits realized from sales of Special Product(s).

 

4.5           Only
one royalty payment shall be owed and payable for a given sale of a Product regardless of the number of MARINA Patent Rights which
are used or included with respect to such Product.

 

4.6           All
amounts due MARINA shall be payable in United States Dollars in Bothell, WA or as MARINA may otherwise direct in writing. When
Products are sold for monies other than United States Dollars, the earned royalties will first be determined in the foreign currency
of the country in which such Products were sold and then converted into equivalent United States Dollars. The exchange rate will
be the United States Dollar buying rate quoted in The Wall Street Journal on the last day of the reporting period.

 

4.7           If
at any time legal restrictions prevent the acquisition or prompt remittance of United States Dollars by MONSANTO with respect to
any country where a Licensed Product is sold, MONSANTO shall pay royalties due to MARINA from MONSANTO’s other sources of
United States Dollars.

 

4.8           MONSANTO
will deliver annual royalty reports to MARINA on or before January 30 of each contract year. Each such royalty report will cover
Sales Revenue in the most recently completed twelve (12) month period and will show: (a) the units, Sales Revenue, and Gross Profits
of each type of Product, including a clear indication of how royalties due hereunder to MARINA were calculated; (b) the calculated
royalties, in U.S. dollars, payable hereunder; (c) the method used to calculate the royalty and other consideration; (d) the
exchange rates used, if any; and (e) any other information reasonably requested by MARINA in support or explanation thereof. Such
report shall also include the identity of all Affiliates contributing to Sales Revenue, the Product rights or scope of the sublicense
granted and the term of the agreement, if any, with such Affiliate.

 

4.9           MONSANTO
shall keep books and records in accordance with generally accepted accounting principles accurately showing all transactions and
information relating to this Agreement. Such books and records shall be preserved for at least five (5) years from the date of
the entry to which they pertain and shall be open to inspection (at MARINA’s option, up to once in each calendar year), by
a reputable third party independent auditor designated by MARINA, at reasonable times and upon reasonable notice to MONSANTO.

 

4.10         The
fees and expense incurred by MARINA and the reasonable out-of-pocket expenses incurred by MONSANTO in retrieving records kept over
three (3) years in connection with any such audit shall be borne solely by MARINA. However, if an error in royalties of more than
[***] percent ([***]%) of the total royalties due for any year is discovered, then the fees and expenses of the audit shall be
borne by MONSANTO and MONSANTO shall pay to MARINA the amount of the royalty payment discrepancy within forty-five (45) days after
receipt of the auditor’s report. If, however, it is discovered that the royalties paid to MARINA by License during the relevant
period exceeded the amount which was properly owed by MONSANTO by [***] percent ([***]%) or more, then MARINA will credit any such
excess amount to MONSANTO’s royalty obligation during the immediately following contract year.

 

    	8

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

4.11         If
MONSANTO receives a payment from a Third Party as consideration for the grant of a sublicense of the MARINA Patent Rights or MARINA
Technology and the amount of said payment is not based upon the manufacture, use, sale or other transfer of a Product resulting
in Sales Revenue hereunder, MARINA shall receive [***] percent ([***]%) of the amount of such payment.

 

5.          IMPROVEMENTS

 

5.1           All
Joint Improvements shall be the sole and exclusive property of MONSANTO. The Party first obtaining knowledge of any Joint Improvement
made during the Term of this Agreement shall promptly notify the other Party in writing of any such Joint Improvement. All right,
title and interest of MARINA in and to any Joint Improvement, including patent rights and other intellectual property rights, shall
be assigned, and is hereby assigned, by MARINA solely and exclusively to MONSANTO, and shall be subject to MARINA’s license
rights as set forth in Article 2.

 

5.2           All
Improvement(s) other than Joint Improvements shall be the sole and exclusive property of the Party making such Improvement(s).

 

6.          VALIDITY

 

6.1           If
a judgment or decree is entered in any proceeding in which the validity or infringement of any claim of an issued patent within
the MARINA Patent Rights has been questioned, which judgment or decree becomes not further reviewable through the exhaustion of
all permissible applications for rehearing or review by a superior tribunal or through the expiration of the time permitted for
any such application (such a judgment or decree being hereinafter referred to as an “Irrevocable Judgment”), the construction
placed on any claim by such Irrevocable Judgment shall thereafter be binding on the Parties as to such claim. If an Irrevocable
Judgment shall hold any such claim invalid, MONSANTO shall be relieved thereafter, in the jurisdiction(s) to which such Irrevocable
Judgment applies, from performing any other acts or making any payment(s) otherwise required by this Agreement because of such
claim(s). MONSANTO shall not, however, be relieved from paying any royalties that accrued before such Irrevocable Judgment or that
are based on another patent or claim not involved in such Irrevocable Judgment.

 

7.          PATENT
PROSECUTION AND MAINTENANCE

 

7.1           MARINA
shall have the primary right and responsibility to prepare, file, prosecute, and maintain all patent applications and issued patents
comprising MARINA Patent Rights using counsel of its choice. MARINA shall, however, use good faith efforts to (a) provide MONSANTO
with a reasonable opportunity to review material actions required or proposed to be taken by MARINA affecting the scope, content
or maintenance of any patent application or issued patent within the MARINA Patent Rights and to provide input with respect thereto
and (b) promptly upon MONSANTO’s written request, supply to MONSANTO copies of all papers received and filed in connection
with such material actions in sufficient time for MONSANTO to comment thereon. MARINA shall also provide reports not more frequently
than once every six (6) months in order to keep MONSANTO reasonably advised as to all developments with respect to MARINA Patent
Rights and shall promptly supply relevant papers in response to all reasonable questions or requests with respect to such reports.
To the extent information relating to any MARINA Patent Rights is publicly available via the Internet, or can be made available
to MONSANTO via the Internet on a password protected basis, MARINA shall be deemed to fulfill all of its obligations set forth
in this Article 7.1 by providing MONSANTO with all information reasonably necessary to access such information via the Internet.

 

    	9

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

7.2           MONSANTO
shall have the primary right and responsibility to prepare, file, prosecute, and maintain all patent applications and issued patents
comprising JOINT Patent Rights using counsel of its choice. MONSANTO shall, however, use good faith efforts to (a) provide MARINA
with a reasonable opportunity to review material actions required or proposed to be taken by MONSANTO affecting the scope, content
or maintenance of any patent application or issued patent within the JOINT Patent Rights and to provide input thereto and (b) promptly
upon MARINA’s written request, supply to MARINA copies of all papers received and filed in connection with such material
actions in sufficient time for MARINA to comment thereon.. MONSANTO shall also provide reports not more frequently than once every
six (6) months in order to keep MARINA reasonably advised as to all developments with respect to JOINT Patent Rights and shall
promptly supply relevant papers in response to all reasonable questions or requests with respect to such reports. To the extent
information relating to any JOINT Patent Rights is publicly available via the Internet, or can be made available to MARINA via
the Internet on a password protected basis, MONSANTO shall be deemed to fulfill all of its obligations set forth in this Article
7.2 by providing MARINA with all information reasonably necessary to access such information via the Internet.

 

7.3           MARINA
shall bear the cost of preparing, filing, prosecuting, and maintaining all patent applications and/or patents comprising the MARINA
Patent Rights, including the cost of interferences and oppositions relating thereto, and MONSANTO shall bear the cost of preparing,
filing, prosecuting, and maintaining all patent applications and/or patents comprising the Joint Patent Rights, including the cost
of interferences and oppositions relating thereto. Notwithstanding the above, (i) to the extent MARINA files a patent application
in any non-US jurisdiction or undertakes any re-examination proceedings or other patent prosecution matters, in each case at the
behest of MONSANTO, or solely for the benefit of the use of MARINA Patent Rights in the Field, MONSANTO shall reimburse MARINA
for all costs and expenses, including fees of patent agents and attorneys, translations and filing fees, incurred in connection
with such prosecution promptly upon receipt of an invoice therefor supported by documentation reasonably acceptable to MONSANTO
and (ii) in the event that MARINA fails to qualify as a small entity filer under the regulations of the United States Patent and
Trademark Office solely as a result of this Agreement (or this Agreement has a similar effect in any other jurisdiction) with respect
to a patent or patent application, MONSANTO agrees to reimburse MARINA for all incremental official governmental fees or costs
incurred by MARINA in connection with such patent or patent application as a result of such disqualification (or effect).

 

    	10

    	 

    
 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

7.4           If
MARINA elects not to (a) prepare or file any patent application with respect to any MARINA Patent Rights or MARINA Improvement
in any territory as to which MONSANTO has requested that MARINA prepare and file a patent application with the United States Patent
and Trademark Office or a foreign patent office, (b) continue prosecution of a patent application in a specific territory with
respect to any MARINA Patent Rights or (c) maintain any issued U.S. or foreign patent among the MARINA Patent Rights, then
MARINA shall so notify MONSANTO at least forty-five (45) days prior to the date on which the failure to make such filing or continue
such prosecution or maintenance, as the case may be, will result in a time bar, as to the filing of an initial patent application,
or the passage of non-extendable deadline with respect to prosecution or maintenance of a pending or issued patent. Thereafter,
if MONSANTO desires to have MARINA nevertheless file patent applications for, continue prosecution of or maintain such MARINA Patent
Rights in the relevant territory, MONSANTO shall so notify MARINA in writing. Upon receipt of MONSANTO’s written notice,
and so long as such notice is provided at least thirty (30) days in advance of the date on which any particular action must be
taken in order to avoid a time bar or the passage of a non-extendable deadline, MARINA shall prepare and file a patent application
for, or continue the prosecution or maintenance of, such MARINA Patent Rights, as the case may be, and MONSANTO shall reimburse
MARINA for all costs and expenses (including fees of patent agents and attorneys, translations and filing fees) incurred in connection
with such preparation and filing of applications for, and/or the prosecution and maintenance of, such MARINA Patent Rights promptly
upon receipt of an invoice therefor supported by documentation reasonably acceptable to MONSANTO. In the event MARINA thereafter
offers for sale or sells a Product in such territory, and such Product is covered by one or more valid claims of any MARINA Patent
Rights the cost and expenses for which were reimbursed to MARINA pursuant to this Article 7.4, MARINA shall thereafter promptly
repay to MONSANTO an amount equal to all amounts previously reimbursed to MARINA by MONSANTO in accordance with this Article 7.4,
and MONSANTO shall thereafter no longer be obligated to reimburse MARINA for such costs and expenses hereunder.

 

7.5           If
MONSANTO elects not to (a) prepare or file any patent application with respect to any JOINT IMPROVEMENT in any territory as to
which MARINA has requested that MONSANTO prepare and file a patent application with the United States Patent and Trademark Office
or a foreign patent office, (b) continue prosecution of a patent application in a specific territory with respect to any JOINT
Patent Rights or (c) maintain any issued U.S. or foreign patent among the JOINT Patent Rights, then MONSANTO shall so notify
MARINA in reasonably sufficient time for MARINA to assume the preparation, filing, prosecution or maintenance of such application
or patent in such territory at MARINA’s expense and with counsel of MARINA’s choice. MARINA shall thereafter have the
option, at its expense and discretion, to have the applicable patent application or issued patent, solely in such territory, assigned
by MONSANTO to MARINA, and MARINA shall thereafter have the primary right and responsibility to prepare, file, foreign file, prosecute
or maintain any such applications or patents in such territory. MONSANTO agrees to execute, and agrees to use reasonable efforts
to cause its employees to execute, all documents necessary to perfect and evidence such assignment and to perfect the filing of,
to advance the prosecution of, or to effect the issuance of such applications in such territory and to take any and all reasonable
action to cooperate with MARINA to obtain or maintain such patent rights in such territory, at MARINA’s sole cost and expense.
Effective upon the assignment of any such patent or patent application from MONSANTO to MARINA pursuant to this paragraph, such
patent or patent application shall be comprised by the MARINA Patent Rights.

 

    	11

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

8.          PATENT
MARKING

 

8.1           MONSANTO
shall mark all Products made, used, or sold under the terms of this Agreement, or their containers, with the numbers of any patents
comprised by the MARINA Patent Rights, in accordance with the applicable patent marking laws of the country(ies) in which said
Products are made, used or sold.

 

8.2           MARINA
shall mark all products made, used, or sold under the terms of this Agreement or their containers, with the numbers of any patents
comprised by the Joint Patent Rights, in accordance with the applicable patent marking laws of the country(ies) in which said products
are made, used or sold.

 

9.          PATENT
INFRINGEMENT

 

9.1           The
Parties shall inform one another promptly and in writing of any alleged infringement of any of the MARINA Patent Rights by a Third
Party in the Field and of any available evidence thereof. The Parties shall not notify any Third Party regarding any such infringement
without the other Party’s consent, which consent will not be unreasonably withheld, and they shall cooperate to attempt to
stop any such infringement without litigation.

 

9.2           During
the term of this Agreement, MARINA shall have the right, but shall not be obligated, to prosecute at its own expense any such infringements
of any of the patent rights referred to in Article 9.1. If MARINA prosecutes any such infringement, MONSANTO agrees that MARINA
may include MONSANTO as a co-plaintiff in any such suit, without expense to MONSANTO. No settlement, consent judgment or other
voluntary final disposition of the suit may be entered into without MONSANTO’s consent, which consent shall not unreasonably
be withheld. The total cost of any such infringement action commenced or defended solely by MARINA shall be borne by MARINA.

 

9.3           If
within six (6) months after having been notified of any alleged infringement and being provided by MONSANTO with substantial evidence
thereof, and if MARINA has been unsuccessful in persuading the alleged infringer to desist and has not brought suit and is not
diligently prosecuting an infringement action, or if MARINA shall notify MONSANTO in writing at any time prior thereto of its intention
not to bring suit against any alleged infringer, then, and under those circumstances only, MONSANTO shall have the right, but shall
not be obligated, to prosecute at its own expense any alleged infringement of the MARINA Patent Rights, and MONSANTO may, for such
purposes, join MARINA as co-plaintiff at no cost to MARINA. No settlement, consent judgment or other voluntary final disposition
of the suit may be entered into without the consent of MARINA, which consent shall not unreasonably be withheld. MONSANTO shall
indemnify MARINA against any order for costs that may be made against MARINA in such proceedings.

  

    	12

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

9.4           Except
as otherwise agreed to by the Parties as part of a cost-sharing arrangement, or as otherwise provided in Article 9.5, any recovery
realized as a result of such litigation, after reimbursement of any litigation expenses incurred by MONSANTO or MARINA, shall be
retained by the party that brought and controlled such litigation for purposes of this Agreement, except that any recovery realized
by MONSANTO as a result of such litigation, after reimbursement of the parties’ litigation expenses, shall be treated as
Sales Revenue for purposes of this Agreement.

 

9.5           In
the event that, after using reasonable efforts to stop the infringement by other means, MONSANTO commences an action in accordance
with Article 9.3 against an alleged infringer who is selling Products in a country, then so long as MONSANTO is diligently pursuing
such action, MONSANTO may withhold from the royalties otherwise thereafter due MARINA hereunder in the country or countries where
the infringement actions are filed and where such actions are being pursued (the “Applicable Royalty Stream”), an amount
equal to not more than up to [***] percent ([***]%) of its actual, reasonable outside attorneys’ fees, incurred directly
in connection therewith, provided, that the aggregate amount which MONSANTO may withhold in any period may not exceed [***] percent
([***]%) of the amount of the Applicable Royalty Stream for such period. Said withholding of royalties shall begin no earlier than
the date such litigation commences. Any recovery or damages by MONSANTO for any such suit shall be applied first in satisfaction
of any unreimbursed outside legal fees of MONSANTO for such suit, and next toward reimbursement of MARINA for any royalties past
due or withheld and applied pursuant to this Article. The balance remaining from any such recovery shall be subject to Article
9.4.

 

9.6           In
the event that a declaratory judgment action alleging invalidity or noninfringement of any of the MARINA Patent Rights is brought
against MONSANTO, then MARINA, at its option, shall have the right, within thirty (30) days after commencement of such action,
to intervene and to control the sole defense of the action at its own expense.

 

9.7           In
any infringement suit that either Party may institute to enforce any of the MARINA Patent Rights pursuant to this Agreement, the
other Party hereto shall, at the request and expense of the Party initiating such suit, cooperate in all respects and, to the extent
possible, have its employees testify when requested and make available relevant evidence, records, papers, information, samples,
specimens, and the like.

 

10.         CONFIDENTIALITY

 

10.1         “Confidential
Information” shall mean this Agreement and all ideas, information, knowledge and discoveries, whether or not patentable,
and any other information (a) relating to unpublished patent applications within the MARINA Patent Rights or covering any
MARINA Technology, (b) that is generally unknown to the public, (c) that either Party marks as “Confidential” or “Proprietary”,
or (d) that by its own nature or by the circumstances surrounding its disclosure ought, in good faith, to be treated as confidential.
Confidential Information includes without limitation product specifications, manufacturing or processing procedures, methods, equipment,
compositions, technology, business plans, marketing plans, cost and pricing information, internal memoranda, formulas, development
programs, sales methods, customer lists, mailing lists, customer usages and requirements, computer programs, privileged communications
and work product on environmental, intellectual property, and product liability issues, and other confidential technical or business
information.

 

    	13

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

10.2         Disclosures.
Except as expressly provided herein, each Party hereby covenants that it will not at any time disclose to any person or use any
Confidential Information owned by the other Party, whether or not such information is embodied in writing or other physical form.
Each Party understands and acknowledges that such Confidential Information may or may not be labeled as “confidential”
and will treat all such Confidential Information as confidential unless otherwise informed by the disclosing Party. For avoidance
of doubt, nothing in this Article 10.2 shall operate to prohibit a Party from any use or disclosure of its own Confidential Information.

 

10.3         Publicity.
Subject to the remainder of this Article 10.3, neither Party shall issue or cause the publication of any press release or public
announcement relating in any way to the entry of this Agreement or the transactions contemplated hereby without the prior written
approval of the other Party, which approval shall not be unreasonably withheld or delayed. Each Party may make public disclosures
of the existence and terms of the Agreement in its respective reports or other filings filed with the Securities and Exchange Commission,
provided that each Party shall first consult with the other on the provisions of this Agreement to be redacted in connection with
any such filings. In addition, the Parties shall consult and use good faith efforts to agree in advance in writing upon the content
of any disclosures regarding the status of development, manufacture or commercialization of Products to be made in such filings
or in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls,
consistent with their respective legal obligations. The Parties agree that the press release annexed hereto as Schedule 10.3
is approved.

 

10.4         Remedies.
Each Party acknowledges and agrees that the damages resulting from any breach of the foregoing covenants may be intangible in whole
or in part and that the disclosing Party is entitled to seek specific enforcement, injunctive relief and other equitable remedies
in addition to monetary damages and legal remedies, and the receiving Party hereby stipulates to the entering of such injunctive
relief enforcing the provisions of this Article 10.

 

10.5         Exclusions.
The preceding obligations to maintain such Confidential Information in confidence shall not apply to the extent that (a) the
information is or becomes in the future public knowledge through no fault or omission of the receiving Party, (b) the information
has been lawfully obtained by the receiving Party from a third party who has the right to disclose such information to the receiving
Party without an obligation of confidentiality, (c) the information is required to be disclosed by an order of a court of competent
jurisdiction, after the disclosing Party has been given notice of such order and an opportunity to seek a judicial remedy preventing
such disclosure.

 

    	14

    	 

    
 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

11.         TERM
OF THE AGREEMENT

 

11.1         Unless
otherwise terminated by operation of law or by an act or acts of the Parties in accordance with the provisions of this Agreement,
this Agreement shall be in force from the Effective Date and shall remain in effect in each country within the Territory, on a
country by country basis, until the expiration of the last-to-expire patent or abandonment of the last patent application licensed
under this Agreement in each such country.

 

11.2         Any
expiration or termination of this Agreement shall not affect the rights and obligations set forth in the following Articles:

 

Article 2      Grant

Article 10    Confidentiality

 Article 15    Lien

Article 16    Remedies

Article 17     Export Control

 

12.         TERMINATION
BY MONSANTO

 

12.1         MONSANTO
shall have the right at any time to terminate this Agreement in whole or as to any portion of the MARINA Patent Rights by given
prior written notice thereof to MARINA, with termination becoming effective three (3) months from the date of the notice.

 

12.2         Any
termination pursuant to the above paragraph shall not relieve MONSANTO of any obligation or liability accrued hereunder prior to
such termination or rescind anything done by MONSANTO or any payments made to MARINA hereunder prior to the time such termination
becomes effective, and such termination shall not affect in any manner any rights of MARINA arising under this Agreement prior
to such termination.

 

12.3         Upon
termination of this Agreement by MONSANTO, MONSANTO shall have the duty of disposing of all previously made or partially made Products
within a period of one hundred and eighty (180) days after the effective date of termination.

 

13.         USE
OF NAMES, TRADEMARKS

 

13.1         Nothing
contained in this Agreement shall be construed as granting any right to either Party to use in advertising, publicity, or other
promotional activities any name, trade name, trademark, or other designation of the other Party or any of the other Party’s
units (including contraction, abbreviation or simulation of any of the foregoing).

 

14.         REPRESENTATIONS
AND WARRANTIES

 

14.1         Each
Party hereby respectively represents and warrants to the other Party:

 

(a)          Such
Party has the legal authority to enter into this Agreement, and this Agreement has been duly executed and delivered by such Party
and constitutes a valid and binding agreement enforceable against such Party in accordance with its terms.

 

    	15

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

(b)          No
authorization or approval from any third party is required in connection with such Party’s execution, delivery, or performance
of this Agreement, except such authorizations or approvals as have been obtained.

 

(c)          The
execution, delivery, and performance of this Agreement by such Party does not violate the laws of any territory or the terms or
conditions of any other agreement to which such Party is a party or by which it is otherwise bound.

 

(d)          Such
Party is not involved in any legal action, the subject matter of which prevents it from entering into this Agreement or from performing
and fulfilling its duties and obligations under this Agreement.

 

(e)          There
is no lien, conveyance, mortgage, assignment, contract or agreement that would prevent or impair it from entering into and carrying
out this Agreement; nor has such Party granted any right to a third party that would conflict with the rights granted to the other
Party under this Agreement.

 

(f)          Disclaimers.
Each Party acknowledges that the MARINA Patent Rights, the MARINA Technology, and the Joint Patent Rights and all deliverables
provided pursuant to the Research Program are provided to it on an “AS IS” basis. NEITHER PARTY MAKES ANY REPRESENTATION
OR WARRANTY, EXPRESS, IMPLIED, ORAL OR WRITTEN, AT LAW OR IN EQUITY, WITH RESPECT TO THE MARINA PATENT RIGHTS, MARINA TECHNOLOGY,
JOINT PATENT RIGHTS, ANY DELIVERABLE PROVIDED PURSUANT TO THE RESEARCH PROGRAM OR ANY PRODUCT OR PROCESS, INCLUDING, WITHOUT LIMITATION,
ANY AND ALL WARRANTIES OF MERCHANTABILITY, REASONABLE CARE, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, VALIDITY, SCOPE,
ENFORCEABILITY, OR FREEDOM TO OPERATE (WHETHER OR NOT SUCH PARTY KNOWS, HAS REASON TO KNOW, HAS BEEN ADVISED, OR IS OTHERWISE IN
FACT AWARE OF ANY SUCH PURPOSE), AND ALL SUCH REPRESENTATION OR WARRANTY IS HEREBY EXPRESSLY DISCLAIMED. 

 

14.2         Marina
expressly represents and warrants to Monsanto that the Intellectual Property licensed hereunder has never been used, adapted for
use or commercialized in the Field, and that the MARINA Patent Rights and MARINA Technology have been developed and applied only
within the field of human and veterinary therapeutic applications.

 

15.         LIEN

 

15.1         As
collateral security for the prompt and complete performance when due of MARINA’s obligations under this Agreement, MARINA
hereby unconditionally grants, assigns and pledges to Monsanto a continuing security interest in all of MARINA’s right, title
and interest in and to (a) the License (i.e., MARINA's interests as Licensor in the License), (b) the MARINA Patent Rights and
MARINA Technology in the Field and (c) all of the proceeds and products, whether tangible or intangible, of the foregoing, including
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing,
including, without limitations, all rights to sue and recover at law or in equity for any past, present and future infringement,
misappropriation, dilution, violation or other impairment thereof in the Field (the “Collateral”). In furtherance of
the foregoing, MARINA shall, concurrent with its execution and delivery of this Agreement, execute and deliver a security agreement
to MONSANTO, which security agreement shall be in the form agreed to between the parties.

 

    	16

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

16.         REMEDIES
FOR BREACH

 

16.1         In
the event MARINA breaches any of its representations, warranties, covenants, and agreements contained in this Agreement:

 

(a)   Subject to Article 16.4,
MONSANTO may exercise in respect of the Collateral, in addition to other rights and remedies provided for in this Agreement, or
otherwise available to it, all the rights and remedies of a secured party on default under the Uniform Commercial Code as in effect
in the State of New York (the “Code”) or any other applicable law.  Without limiting the generality of the foregoing,
MARINA expressly agrees that, in any such event, MONSANTO without demand of performance or other demand, advertisement or notice
of any kind (except a notice specified below of time and place of public or private sale) to or upon MARINA or any other Person
(all and each of which demands, advertisements and notices are hereby expressly waived to the maximum extent permitted by the Code
or any other applicable law), may take immediate possession of all or any portion of the Collateral and (i) require MARINA
to, and MARINA hereby agrees that it will at its own expense and upon request of MONSANTO forthwith, assemble all or part of the
Collateral as directed by MONSANTO and make it available to MONSANTO at one or more locations as designated by MONSANTO, and (ii) without
notice except as specified below, sell or otherwise dispose of the Collateral or any part thereof in one or more parcels at public
or private sale or other disposition, at any of MONSANTO’s offices or elsewhere, for cash, on credit, and upon such other
terms as MONSANTO may deem commercially reasonable. Without limiting the generality of the foregoing, MONSANTO may disclaim any
and all representations and warranties in connection with any such sale or other disposition.  MARINA agrees that, to the
extent notice of sale shall be required by law, at least ten (10) days notice to MARINA of the time and place of any public
sale or the time after which any private sale is to be made shall constitute reasonable notification and specifically such notice
shall constitute a reasonable “authenticated notification of disposition” within the meaning of Section 9-611
of the Code.  MONSANTO shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. 
MONSANTO may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such
sale may, without further notice, be made at the time and place to which it was so adjourned.

 

(b)      MONSANTO
is hereby granted a license or other right to use, without liability for royalties or any other charge, MARINA’s labels,
patents, copyrights, rights of use of any name, trade secrets, trade names, trademarks, service marks and advertising matter, URLs,
domain names, industrial designs, other industrial or intellectual property or any property of a similar nature, whether owned
by MARINA or with respect to which MARINA has rights under license, sublicense, or other agreements, (but only to the extent (i) such
license, sublicense or agreement does not prohibit such use by MONSANTO and (ii) MARINA will not be in default under such
license, sublicense or other agreement as a result of such use by MONSANTO) as it pertains to the Collateral, in preparing for
sale, advertising for sale and selling any Collateral, and MARINA’s rights under all licenses and all franchise agreements
shall inure to the benefit of MONSANTO.

 

    	17

    	 

    
 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

(c)      In
the event the proceeds of Collateral are insufficient to satisfy all of MARINA’s obligations in full, MARINA shall remain
jointly and severally liable for any such deficiency.

 

(d)  MARINA hereby acknowledges that
the obligations arose out of a commercial transaction.

 

16.2         MARINA
irrevocably authorizes MONSANTO at any time and from time to time in the sole discretion of MONSANTO and appoints MONSANTO as its
attorney in fact (i) to execute on behalf of MARINA as debtor and to file financing statements necessary or desirable in MONSANTO's
sole discretion to perfect and to maintain the perfection and priority of MONSANTO's security interest in the Collateral, (ii)
to endorse and collect any cash proceeds of the Collateral, (iii) to file a carbon, photographic or other reproduction of this
Agreement or any financing statement with respect to the Collateral as a financing statement and to file any other financing statement
or amendment of a financing statement (which does not add new collateral or add a debtor) in such offices as MONSANTO in its sole
discretion deems necessary or desirable to perfect and to maintain the perfection and priority of MONSANTO's security interest
in the Collateral, (iv) to apply the proceeds of any Collateral received by MONSANTO to the secured obligations, (v) to discharge
past due taxes, assessments, charges, fees or liens on the Collateral, (vi) to exercise all of MARINA's rights and remedies with
respect to the collection of any Collateral, including, without limitation, executing and delivering instruments of assignment
or conveyance in respect of the Collateral, (vii) to change the address for delivery of mail addressed to MARINA to such address
as MONSANTO may designate and to receive, open and dispose of all mail addressed to MARINA, and (viii) to do all other acts and
things necessary to carry out this Agreement; and MARINA agrees to reimburse MONSANTO on demand for any payment made or any expense
incurred by MONSANTO in connection with any of the foregoing; provided that, this authorization shall not relieve MARINA of any
of its obligations under this Agreement.

 

16.3         All
acts of said attorney or designee are hereby ratified and approved. The powers conferred on MONSANTO under this Article are solely
to protect MONSANTO's interests in the Collateral and shall not impose any duty upon MONSANTO to exercise any such powers. MONSANTO
agrees that, except for the powers granted in (a)(i)-(v) and (a)(viii) above, it shall not exercise any power or authority granted
to it unless a default has occurred and is continuing.

 

16.4         In
the event that MONSANTO exercises its rights as a secured creditor pursuant to the Article 16, it will take all actions necessary
to ensure that MARINA retains or receives a worldwide, perpetual, irrevocable, exclusive license, with the full right to sublicense,
under the MARINA Patent Rights and the MARINA Technology outside the Field, (a) to make, have made, use, import, export, sell,
and have sold products outside the Field and (b) to use the MARINA Patent Rights and the MARINA Technology outside the Field.

 

    	18

    	 

    
  

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

17.         EXPORT
CONTROL

 

17.1         The
Parties agree that information and materials provided under this agreement may be subject to the export control laws and regulations
of the United States, potentially including but not limited to the Export Administration Regulations ("EAR"), and sanctions
regimes of the U.S. Department of Treasury, Office of Foreign Asset Controls (“OFAC”). The Parties will comply with
these laws and regulations. A Party will provide advance notice to the other Party if they contemplate providing the other Party
with any items classified under an export classification control number (ECCN) other than EAR 99. Neither Party shall, without
prior U.S. government authorization, export, reexport, or transfer information and materials, either directly or indirectly, to
any country subject to a comprehensive U.S. trade embargo (currently Cuba, Iran, North Korea, Sudan, and Syria) or to any person
or entity listed on the "Entity List" or "Denied Persons List" maintained by the U.S. Department of Commerce
or the list of "Specifically Designated Nationals and Blocked Persons" maintained by the U.S. Department of Treasury.
Moreover, neither Party shall, without proper U.S. government authorization, export, reexport, or transfer information and materials
to any resident or national of any country subject to a comprehensive U.S. trade embargo. In addition, information and materials
may not be exported, reexported, or transferred to an end-user engaged in activities related to weapons of mass destruction. The
Parties further agree that this assurance shall remain in effect even after termination of this Agreement.

 

18.         NOTICES

 

18.1         Any
notice or payment required to be given to either party shall be deemed to have been properly given and to be effective (a) on the
date of delivery if delivered in person or (b) five (5) business days after mailing if mailed by first-class certified mail, postage
paid, or the date a confirmed facsimile has been sent, to the respective addresses given below, or to such other address as either
Party shall designate by written notice given to the other Party.

 

	In the case of MONSANTO:	Monsanto Company
	 	Attn.: Vice President, Chemistry
	 	800 N. Lindbergh Blvd.
	 	St. Louis, Missouri 63167
	 	 
	with copies to:	General Patent
Counsel
	 	Monsanto Company
	 	800 N. Lindbergh Boulevard
	 	St. Louis, Missouri 63167
	 	 
	 	Director, Technology Alliances Team
	 	Monsanto Company
	 	800 N. Lindbergh Boulevard, B2NL
	 	St. Louis, Missouri 63167

 

    	19

    	 

    
 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	In the case of MARINA:	Marina Biotech, Inc.
	 	Attn: Chief Executive Officer
	 	3830 Monte Villa Parkway
	 	Bothell, WA 98021
	 	 
	With copies to:	Pryor
Cashman LLP
	 	Attn: Lawrence Remmel
	 	7 Times Square
	 	New York, NY 10036

 

19.         ASSIGNABILITY

 

19.1         This
Agreement is not assignable by MARINA nor shall the rights of MARINA hereunder be sold, assigned, hypothecated, mortgaged, pledged
or otherwise transferred, whether voluntarily or by operation of law, without the express written consent of MONSANTO as determined
within MONSANTO’s sole and absolute discretion. In addition to the foregoing, a Change in Control not acceptable to MONSANTO
as determined by MONSANTO in MONSANTO 's sole and absolute discretion shall constitute an event of default by MARINA hereunder.

 

19.2         This
Agreement is binding upon and shall inure to the benefit of MONSANTO’s successors and assigns, provided, however, this Agreement
shall not be assigned by MONSANTO without the prior written consent of MARINA except that MONSANTO may freely assign this Agreement
to a business entity that acquires all or substantially all of MONSANTO’s business or assets or all or substantially all
of MONSANTO’s business to which this Agreement pertains.

 

20.         WAIVER

 

20.1         It
is agreed that no waiver by either Party hereto of any breach of default of any of the covenants or agreements herein set forth
shall be deemed a waiver as to any subsequent and/or similar breach of default.

 

21.         GOVERNING
LAWS

 

21.1         THIS
AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK but the scope and validity of
any patent or patent application shall be governed by the applicable laws of the country in which any such patent or patent application
is or was filed or issued as the case may be.

 

    	20

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

22.         MISCELLANEOUS

 

22.1         The
headings of the several Articles are inserted for convenience of reference only and are not intended to be a part of or to affect
the meaning or interpretation of this Agreement.

 

22.2         This
Agreement will not be binding upon The Parties until it has been signed below on behalf of each Party, in which event, it shall
be effective as of the Effective Date.

 

22.3         No
amendment or modification hereof shall be valid or binding upon The Parties unless made in writing and signed on behalf of each
Party.

 

22.4         This
Agreement embodies the entire understanding of The Parties and shall supersede all previous communications, representations and
understandings, whether oral or written, between The Parties relating to the subject matter hereof.

 

22.5         If
any provision(s) contained in this Agreement shall be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other provision(s) hereof, but this Agreement shall be construed as if such
invalid or illegal or unenforceable provision(s) had never been contained herein.

 

22.6         MARINA
recognizes the importance of the investment which MONSANTO intends to make under this Agreement. Accordingly, MARINA shall use
all reasonable efforts to insure that it will not knowingly take any actions which would unfairly and unreasonably impair, diminish,
frustrate or compromise the rights and licenses granted to MONSANTO under this Agreement.

 

[Signatures on following page]

 

    	21

    	 

    

  

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

IN WITNESS WHEREOF, both MARINA and MONSANTO
have executed this Agreement, in duplicate originals, by their duly authorized representatives on the respective days and in the
year as hereinafter written.

 

	MONSANTO COMPANY	 	MARINA BIOTECH, INC
	 	 	 
	By	 	 	By	/s/ J. Michael French
	(Signature)	 	(Signature)
	 	 	 
	Printed Name	 	 	Printed Name:  J. Michael French
	 	 	 
	Title	 	 	Title:  President & CEO
	 	 	 
	Date	 	 	Date:  May 3, 2012

 

 

	MDRNA RESEARCH, INC	 	CEQUENT PHARMACEUTICALS, INC
	 	 	 
	By	/s/ J. Michael French	 	By	/s/ J. Michael French
	(Signature)	 	(Signature)
	 	 	 
	Printed Name: 	 J. Michael French	 	Printed Name:  J. Michael French
	 	 	 
	Title:  	President	 	Title:  President
	 	 	 
	Date: 	 May 3, 2012	 	Date:  May 3, 2012

  

    	22

    	 

    

  

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

MARINA BIOTECH, INC.

SCHEDULE 1.14A – MARINA PATENT RIGHTS

 

	Docket
 No.	 	Title	 	Country	 	Owner	 	Application
 Number	 	Filing
 Date	 	Patent
 Number	 	Date
 Issued	 	Status
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	23

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	24

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	25

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	26

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	27

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

MARINA BIOTECH, INC.

SCHEDULE 1.14B – EXCLUDED PATENT ASSETS

 

	Docket
 No.	 	Title	 	Country	 	Owner	 	Application
 Number	 	Filing
 Date	 	Patent
 Number	 	Date
 Issued	 	Status
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	28

    	 

    

  

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	29

    	 

    

 

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

    	30

    	 

    

  

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

SCHEDULE 1.22

 

Marina Biotech/Monsanto Research Plan

 

[***]

 

    	31

    	 

    

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

SCHEDULE 10.3 – PRESS RELEASE

 

Marina Biotech Announces Worldwide Exclusive
Licensing 

Agreement with Monsanto 

 

Bothell, WA, May 8, 2012 – Marina Biotech, Inc. (OTCQX:
MRNA) announced today that it has entered into an exclusive licensing agreement with Monsanto Company for Marina Biotech’s
delivery and chemistry technologies. Terms of the agreement were not disclosed.

 

“We are pleased to enter into this agreement with Monsanto,
a global leader in agriculture and crop sciences,” stated J. Michael French, President and Chief Executive Officer of Marina
Biotech. “Over the last several years, we have been focused on bringing together novel chemistry and delivery technologies
necessary to broadly apply our discovery platform across the life sciences sector. We view this license as yet another important
validation of this platform and we look forward to a strong and growing relationship with Monsanto.”

 

About Marina Biotech, Inc. 

Marina Biotech is a biotechnology company focused on the development
and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference
(RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial
Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs — in bladder cancer and malignant ascites. Marina
Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder
cancer program. In addition, Marina Biotech has entered into an agreement with both Mirna Therapeutics and ProNAi Therapeutics
to license Marina Biotech’s SMARTICLES® technology for the delivery of microRNA mimics and DNAi, respectively.
Marina Biotech’s goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and
drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina
Biotech is available at http://www.marinabio.com.

 

Forward-Looking Statements 

Statements made in this news release may be forward-looking
statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors
that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to
differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to
obtain additional funding in the near term; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research,
development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product
research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech
and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and
commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause
actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina
Biotech’s most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission.
Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

 

    	32

    	 

    

 

 

[CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***],
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

 

Marina Biotech, Inc.

Philip Ranker

Interim Chief Financial Officer

(425) 908-3615

pranker@marinabio.com

 

    	33EXHIBIT 10.1

 

LICENSE
AGREEMENT

 

This LICENSE AGREEMENT (the “Agreement”)
is entered into effective as of September 21, 2012 (the “Effective Date”), between ACCESS BUSINESS GROUP
INTERNATIONAL LLC, a Michigan limited liability company (“Access”) and INTERLEUKIN GENETICS, INC., a Delaware
corporation (“Interleukin”).

 

RECITALS

 

		A.	Interleukin has developed or controls technology relating to its DNA-based Genetic Test, as defined herein, that may be used
for the identification of an individual’s most effective diet and exercise regimen.

 

		B.	Access desires a license under Interleukin’s intellectual property rights in the Genetic Test in accordance with the
terms of this Agreement and Interleukin is willing to grant such a license.

 

		C.	On or around the date of this Agreement, the parties are entering into a professional services agreement (the “Services
Agreement”), pursuant to which Interleukin will be providing certain services to Access.

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the parties hereto agree as follows:

 

Article 1.Definitions

 

		1.1	“Affiliate” shall mean, with respect to the applicable party, any corporation,
company, partnership, trust, sole proprietorship or other entity or individual which directly or indirectly controls, is controlled
by, or is under common control with, a party to this Agreement. For purposes of this definition, “control” means ownership,
directly or through one or more Affiliates, of (a) at least 50% of the shares of stock entitled to vote for the election of directors
in the case of a corporation, or (b) 50% or more of the equity interests in the case of any other type of legal entity or status
as a general partner in any partnership, or (c) any other arrangement whereby a party controls or has the right to control the
Board of Directors or equivalent governing body of a corporation or entity. For purposes of this Agreement, Interleukin shall not
be deemed to be an Affiliate of Access.

  

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule24b-2 of the Securities
Exchange Act of 1934, as amended.

    	1

    	 

    

		1.2	“Direct Sales Channel” shall mean the channel of distribution in which sales are direct to consumers and
where compensation of the seller is based on a multilevel or single level plan that pays it representatives/distributors based
not only on one’s own product sales but on the product sales of one’s “downline” (the people a representative/distributor
has brought into the business and, in turn (if multi-level), the people they have brought into the business) and which includes
sales through websites of Access’s Affiliates and their respective distributors’ websites.

 

		1.3	“Field of Use” shall mean Genetic Tests in the Direct Sales Channel.

 

		1.4	“Genetic Test” means any genomic test used to determine appropriate recipients of a specific weight management
program that includes a diet and exercise regimen (i) the use or sale of which would, absent the license granted to Access hereunder
infringe any claim included in the Interleukin Patents, or (ii) that incorporates any Interleukin Know-How.

 

		1.5	“Interleukin Know-How” shall mean any Know-How owned by Interleukin that is necessary or useful for the
implementation, manufacture or commercialization of Genetic Tests, which may include algorithms or other methods for determining
recommended diet, exercise and lifestyle programs based on genotypes (and any validation standards therefor), test report formats
and content, and protocols for the implementation and verification of genotype testing and genetics laboratories.

 

		1.6	“Interleukin Patents” shall mean the patents listed on Exhibit A attached hereto (which may be amended
upon agreement of the parties) all of which are owned by Interleukin or which Interleukin has the right to grant licenses of the
scope granted in this Agreement. Each Interleukin Patent that is not published or otherwise in the public domain when disclosed
to Access shall be subject to the confidentiality provisions in Article 5 hereof. Such Exhibit A may be amended from time
to time by written agreement of the parties to reflect the granting of patent applications.

 

		1.7	“Interleukin Technology” shall mean the Interleukin Know-How and/or Interleukin Patents, as the case may
be.

 

		1.8	"Improvement" shall mean all patentable and non-patentable inventions, discoveries, technology and information
of any type whatsoever, including without limitation, methods, processes, technical information, knowledge, and know-how which
use, incorporate, derive from or are based on Interleukin Technology or could not be conceived, developed or reduced to practice
but for the use of Interleukin Technology.

 

		1.9	“Know-How” means and includes any and all unpatented (or not specifically taught by a patent) and proprietary
ideas, inventions, discoveries, technology, data, results, formulae, designs, specifications, methods, processes, formulations,
techniques, ideas, know-how, technical information (including, without limitation, structural and functional information), process
information, pre-clinical information, clinical information, and any and all proprietary biological, chemical, pharmacological,
control and manufacturing data and materials. For the avoidance of doubt, Know-How does not include any information as described
in Section 5.5 (a) – (e) hereof.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

    	2

    	 

    

 

		1.10	“License Term” shall have the meaning set forth in Section 7.1 below.

 

		1.11	“Licensed Products” shall mean Genetic Tests that incorporate Interleukin Technology.

 

		1.12	“Territory” shall mean all countries who are members of the European Union, Russia and South Africa.

 

Article 2.LICENSE Grant

 

		2.1.	Grant of License. Subject to the terms and conditions of this Agreement, Interleukin hereby
grants to Access, and Access hereby accepts, a non-exclusive, royalty-bearing, non-transferable (except as permitted in Section
10.10 below) license in the Field of Use, without the right to grant sublicenses, except to Access’s Affiliates, under Interleukin
Technology, to make, have made, use, import, export, sell and offer for sale Licensed Products in the Territory, and to practice
all processes in the use thereof. 

 

		2.2.	Marketing Efforts. Access shall use commercially reasonable efforts to market and sell Licensed
Products. Access shall exercise in good faith reasonable business judgment in marketing and selling the Genetic Tests in the Territory.

 

		2.3	Sublicenses. All sublicenses to Access Affiliates will be in writing, will provide for automatic termination in the
event the Affiliate ceases to be an Affiliate, will not be less restrictive than this Agreement, and will not convey any right
to grant further sublicenses. Within a reasonable period of time, but in no event more than 90 days after execution of any such
sublicense, Access will give Interleukin written notice of the identity of the Affiliate granted the sublicense. Access shall be
responsible for the actions of its sublicensee Affiliates, and any breach of the terms or conditions of this Agreement by an Affiliate
sublicensee of Access shall be deemed to be a breach by Access.

 

		2.4	Limited License. Access agrees that it has no right or license outside the Field of Use and agrees that it will not
use Interleukin Technology outside the Field of Use.

 

		2.5	Marking. Access will comply, to the extent practical, with all marking requirements including 35 USC 287(a) and all
corresponding foreign laws, including marking each Licensed Product with applicable patent numbers included in Interleukin Patents
as set forth in Exhibit A as amended from time to time.

 

		2.6	Restriction on Future Licenses. Pertaining to license grants in Licensed Products, Interleukin agrees not to grant to
any of the companies on the attached Exhibit B a license under the Interleukin Technology to make, have made, use, sell,
offer for sale, export or import Genetic Tests in the Territory and Interleukin further agrees to include such restriction in all
of its licenses of Interleukin Technology for Genetic Tests. Interleukin agrees that Access may from time to time request additions
to Exhibit B and Interleukin shall consider such requests in good faith and approval of such addition shall not be unreasonably
withheld.. Any agreed addition to Exhibit B shall be evidenced by a written amendment to this Agreement.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

    	3

    	 

    

 

 

		2.7	Protection of Interleukin Technology. Notwithstanding anything else, Access agrees that Access, its Affiliates, and
any entities that Access, its Affiliates or Interleukin share or disclose any Confidential Information of Interleukin, including
Interleukin Know-How, in connection with this Agreement or the Services Agreement shall not be permitted (i) to use such Confidential
Information for anything other than as reasonably necessary for Access or such Access Affiliate to exercise its license rights
in the Territory and Field of Use under this Agreement during the License Term, or (ii) to use any of such Confidential Information
after the License Term.

 

Article 3.ROYALTIES

 

		3.1.	Royalties. Access shall pay to Interleukin during the License Term a royalty of US$[***] for each Licensed Product sold
in the Territory by Access or an Affiliate of Access, except that the royalty shall be US$[***]for a Licensed Product if an Interleukin
Patent has issued (and has not expired or been found invalid or unenforceable) in the country in which such Licensed Product is
sold. A Licensed Product will be considered sold when invoiced or otherwise shipped, distributed or used (whichever event occurs
first); except for (i) returns, which are Licensed Products returned to Access by its customer on which Access gives credit to
that customer and are not re-distributed (Access must pay royalties on any returns which are later re-distributed) and (ii) replacements
of Licensed Products distributed by Access or an Access Affiliate under warranty obligations for which Access or any Access Affiliate
does not receive revenue. Payment by Access shall be made within [***] days following each Royalty Period. The “Royalty Period”
shall be defined as January 1-March 31, April 1-June 30, July 1-September 30, and October 1-December 31 of each calendar year.
Access is liable to pay royalties to Interleukin with respect to all Licensed Products initially shipped by Access or an Affiliate
of Access to its independent business owner or end user prior to the termination of this Agreement. Access will furnish Interleukin
a Royalty Report Form as set forth in Schedule 3.1 attached hereto with each royalty payment to support the basis for the payment.
Any amounts not paid by Access when due under this Agreement, will be subject to interest equal to the then existing prime lending
rate as published in The Wall Street Journal, or if less, the maximum interest rate permitted under applicable law, from
the payment due date until the actual date of payment.

 

		3.2	Currency. All payments by Access to Interleukin shall be made in U.S. dollars.

 

		3.3	Taxes. Each payment to be made by Access to Interleukin under this Agreement shall be made
free and clear of and without any deduction, withholding or set-off whatsoever, including for or on account of taxes, unless Access
is required by law to make such a payment subject to a deduction or withholding. If Access is required by law to make a deduction
or withholding of taxes or otherwise from such a payment, Access agrees to provide such assistance, including documents and other
instruments, as are reasonably necessary in order for Interleukin to obtain a refund, credit or benefit of such deduction or withholding
in accordance with applicable law in the relevant jurisdiction.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	4

    	 

    

 

Article 4.RECORDS; AUDIT
RIGHTS

 

		4.1.	Records. Access agrees to keep and maintain complete and accurate records and books of account
in sufficient detail and form so as to enable verification of payment of royalties due to Interleukin pursuant to this Agreement.
Access agrees to maintain such records and books of account for a period of not less than three years following the year to which
the records pertain. For avoidance of doubt, Access shall be responsible for causing its Affiliates to comply with this section.

 

		4.2.	Audit Rights. Access agrees to allow any independent auditor appointed by Interleukin who is
reasonably acceptable to Access, and which is subject to reasonable and appropriate confidentiality terms to inspect such records
and books of account relating to Access’s compliance with the terms of this Agreement for the three years preceding the notification
of the audit, during reasonable business hours, on reasonable advance notice of no less than two weeks. Such inspections shall
be no more frequent than once each calendar year during the term hereof and once within six months after termination of this Agreement.
The designated accountant shall retain in confidence the information in the books of account and shall report to Interleukin only
the accuracy or inaccuracy of the reports rendered pursuant to Section 3.1 hereof. In the event of underpayment by Access, Access
will promptly pay to Interleukin all amounts underpaid. The cost of such audit will be borne by Interleukin, unless such audit
reveals an underpayment of greater than 5% of the total amount determined to be actually due, in which case Access will bear such
cost.

 

Article 5.CONFIDENTIALITY

 

		5.1.	General. Each party recognizes that, in connection with this Agreement and the Services Agreement,
such party may receive access to, or develop, business, technical, and financial information of, from or for the other party, which
the other party considers or will consider confidential or proprietary.

 

		5.2.	Definition. For purposes of this Agreement, “Confidential Information” means
all such information, whether written or oral, which is provided by one party to the other party, designated by the disclosing
party as “Confidential” or that should reasonably be understood based on the nature of the information or the context
of the disclosure to be confidential, including without limitation the Interleukin Technology. In the event that either party provides
sample products, test reports or other equipment or material to the other party, the items so received and any information learned
there from shall be treated as Confidential Information transferred to the receiving party by the disclosing party under this Agreement.

  

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

    	5

    	 

    

 

 

		5.3.	Nondisclosure. Each party, when acting as the receiving party, acknowledges that all Confidential
Information is proprietary and a valuable trade secret of the disclosing party, and that any disclosure or unauthorized use of
Confidential Information will cause the disclosing party irreparable harm and loss. Each party agrees that, when acting as the
receiving party, neither it nor any others associated with or used by it in the performance of this Agreement shall use the Confidential
Information for itself or others or disclose any Confidential Information to others, without first obtaining the prior written
consent of the disclosing party.

 

		5.4.	Use of Confidential Information. Each party, when acting as the receiving party, shall: (a)
use such Confidential Information for the sole and limited purpose of exercising its rights and performing its obligations hereunder;
and (b) certify the destruction of or return all Confidential Information, including copies or other written or physical embodiments
of, or containing, such Confidential Information (including any studies, analyses, compilations or other materials prepared in
whole or in part based on such Confidential Information) to the disclosing party immediately upon the termination of the licenses
granted to the receiving party under this Agreement, except for a single copy thereof which must be thereafter restricted to use
for (i) legal purposes only as a record of the Confidential Information returned under this Agreement and (ii) for replacement
purposes permitted in Section 7.5(b) below.

 

		5.5.	Exceptions. This Agreement shall not affect the receiving party’s rights to use or disclose
information:

 

		(a)	which the receiving party can demonstrate to have been in the public domain through no wrongful act of itself prior to the
date of its disclosure to the receiving party by the disclosing party;

 

		(b)	which the receiving party can demonstrate, by written records predating disclosure to the receiving party by the disclosing
party, to have been in the possession of the receiving party on a non-confidential basis prior to the date of its disclosure;

 

		(c)	which becomes part of the public domain by publication or otherwise not due to any unauthorized act or omission on the part
of the receiving party;

 

		(d)	which the receiving party can demonstrate by written records to have been independently developed by the receiving party without
reference to or reliance upon the Confidential Information of the disclosing party; or

 

		(e)	which the receiving party can demonstrate by written records to have been disclosed to the receiving party on a non-confidential
basis by a third party having a lawful right to do so.

  

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential
treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

    	6

    	 

    

		5.6.	Governmental or Judicial Process. If the receiving party, or its representatives, are compelled
to disclose Confidential Information by governmental or judicial process, the receiving party agrees to promptly provide the disclosing
party with written notice of such requirement to allow sufficient time for the disclosing party to apply for judicial review of
such compelled disclosure, provided that this obligation shall not apply where the receiving party’s compliance with this
obligation itself would be contrary to law or any provision of any regulatory authority.

 

		5.7.	Affiliates. For purposes of this confidentiality provision, “Access” shall be deemed
to include all Affiliates and divisions of Access, and “Interleukin” shall be deemed to include all Affiliates and
divisions of Interleukin.

 

Article 6.Intellectual Property
Rights – INTERLEUKIN TECHNOLOGY

 

		6.1	Ownership of Interleukin Technology. Interleukin shall retain full and exclusive ownership
of all Interleukin Technology. Interleukin shall continue to prosecute all United States and international patent applications
included in the Interleukin Technology and shall bear all of the costs associated with filing, prosecution, issuance and maintenance
of all such patents and patent applications.

 

		6.2	Improvements.

 

		(a)	Each party is the owner of its intellectual property rights, such as patents, patent applications,
copyrights, know-how, trade secrets, registered designs, utility models and any similar protected rights anywhere in the world,
which exist at such party as of the Effective Date hereof, or which are independently created by such party without reference to
or use of the other party’s Confidential Information (“Background IP Rights”). Other than as expressly
set forth in this Agreement, no license, express or implied, is provided to either party’s Background IP Rights.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	7

    	 

    

		(b)	Any Improvement made by or on behalf of Interleukin during the License Term (“Interleukin Improvement”)
will be owned by Interleukin. Any Improvement made by or on behalf of Access during the License Term (“Access Improvement”)
will be owned by Access. Any Improvement made jointly by, or on behalf of, Interleukin and Access during the License Term (“Joint
Improvements”) shall be jointly owned by Interleukin and Access; provided, for avoidance of doubt, if such Improvements were
made subject to a separate agreement between the parties, then the terms of such agreement shall govern with respect to such Improvements.
Each party will disclose any Improvement made by it to the other party promptly after a patent application with respect to such
Improvement has been filed or the Improvement has been reduced to practice, whichever is earlier. Interleukin will have the right
to control the obtaining and maintaining of patents on Joint Improvements and will use reasonable efforts to keep Access advised
of all material actions with respect thereto. Interleukin will advise Access in writing (“Interleukin Notice”) of the
jurisdictions in which it proposes to seek patent protection for a Joint Improvement sufficiently in advance of any irredeemable
loss of rights such that Access may in writing advise Interleukin of additional jurisdictions in which Access wants patent protection
for such Joint Improvement (“Access Notice”), and Interleukin will consider such requests in good faith. Any patent
obtained on a Joint Improvement will be jointly owned. Each party hereby grants to the other party all rights to exploit any jointly-owned
patent claiming a Joint Improvement to the fullest extent without accounting to the other party except as expressly provided herein,
but for avoidance of doubt, the foregoing grant shall not grant or imply any licenses to any other patents or technology of either
party. The parties will share equally all reasonable costs associated with obtaining and maintaining patents on Joint Improvements;
Access will reimburse Interleukin for one-half of all costs incurred, within 60 days after receipt of an invoice therefor. One
party, by written notice to the other party, may elect not to continue to share in such costs for a particular jointly owned patent
or patent application. The one party will assign its entire interest in such patent or patent application to the other party promptly
after receipt from the other party of a written request therefor.

 

		6.3	Reservation of Rights. Neither party grants to the other party any rights in any intellectual property, including without
limitation any patents, patent applications, trademarks or trade names, except those rights that are specifically set forth in
this Agreement.

 

article 7.term and termination

 

		7.1.	License Term. Unless earlier terminated or extended as provided herein, the term of this Agreement
shall begin on the Effective Date and continue for five (5) years after the date of first commercial sale by any Affiliate of Access
(the “Initial Term”). Thereafter, this Agreement shall automatically renew for additional one-year renewal terms
unless either party provides written notice to the other party of intent to terminate at least 60 days prior to the end of the
relevant license period (the Initial Term plus each renewal period, if any, referred to herein as the “License Term”).

 

		7.2	Termination for Breach. In the event of a material breach of this Agreement, the non-breaching party shall be permitted
to terminate this Agreement if the breach is not cured within 30 days after the date of prior written notice given to the breaching
party.

 

		7.3.	Termination for Bankruptcy, Etc. Either party shall have the right to terminate this Agreement with 60 days prior written
notice in the event of insolvency, bankruptcy, liquidation, appointment of receiver and attachment, of or for the other party.

 

		7.4	Termination by Access. In the event Access determines in its sole discretion that it is unable to sell the Licensed
Product in any market due to regulatory issues, or if it determines that there is no reasonable likelihood that a patent will issue
in the United States in connection with the Interleukin Technology, then Access may terminate this Agreement by providing at least
10 days prior written notice to Interleukin. Access shall have the right to terminate this Agreement, without cause, on 90 days
prior written notice to Interleukin.

  

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

    	8

    	 

    

 

 

7.5.Consequences
of Termination.

 

		(a)	Upon expiration or termination of the License Term the licenses and rights granted to either party
hereunder, and the royalties for such licenses and rights, will automatically terminate and each party shall certify the destruction
of or return all Confidential Information of the other party in accordance with the terms of Article 5.

 

		(b)	In the case of any termination or expiration of the License Term, other than termination by Interleukin
under Section 7.2 above, the right of the IBOs of Access’s Affiliates and end-user customers to use Licensed Products initially
shipped by Access or Access’s Affiliates before termination will not be affected and Access shall have the right to sell
through its inventory of Licensed Products as of the date of termination for a period of twelve (12) months, subject to the payment
of royalties under Article 3. Access shall further have the right to secure the services of a third party to process Genetic Tests
during such 12-month period, subject to all of the obligations and restrictions under this Agreement, including restrictions on
use of Confidential Information and requirements to destroy or return all Confidential Information.

 

		(c)	Upon termination of this Agreement by either party, the other party shall certify the destruction
of or return all Confidential Information of the terminating party in accordance with the terms of Article 5.

 

		7.6.	Survival. The provisions of Articles 1, 3 (with respect to the payment of royalties provided
for in Sections 7.5(b) and 7.5(c) and any royalty amounts accrued as of the date of termination), 4, 5, 6, 8, 9 and 10 and Sections
2.7, 7.5 shall survive the expiration or other termination of this Agreement.

 

ARTICLE 8.REPRESENTATIONS
AND WARRANTIES

 

		8.1.	Representations and Warranties of Interleukin. Interleukin represents and warrants to Access
as follows:

 

		(a)	it is duly organized, validly existing and in good standing under the laws of the State of Delaware;

 

		(b)	it has completed all actions and procedures, corporate and otherwise, and has obtained all consents
or other authorization necessary or proper to authorize the grant of the license and other rights hereunder and to enable it to
perform all of its obligations hereunder;

  

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	9

    	 

    

 

 

		(c)	it has the right to grant the License and other rights hereunder with respect to the Interleukin Technology
and such grant by Interleukin does not violate or constitute an event that is or would be, with the passage of time or the giving
of notice or both, a violation, breach or default of, any agreement or obligation to which Interleukin is a party or by which it
is bound;

 

		(d)	to the knowledge of Interleukin, the grant of the License and other rights hereunder is not in violation
of any law, rule, regulation or court order, local, state or federal; and

 

		(e)	it has no knowledge of any basis for invalidity or unenforceability of the patents included in the
Interleukin Technology.

 

		8.2.	Representations and Warranties of Access. Access represents and warrants to Interleukin as
follows:

 

		(a)	it is a limited liability company duly organized, validly existing and in good standing under the
laws of Michigan; and

 

		(b)	it has completed all actions and procedures, corporate and otherwise, and has obtained all consents
or other authorization necessary or proper to authorize the grant of the license and other rights hereunder and to enable it to
perform all of its obligations hereunder.

 

		8.3.	Disclaimers. Nothing contained in this Agreement shall be construed as:

 

		(a)	a warranty or representation that any manufacture, offer for sale, sale, use, lease, importation,
or other disposal of any Licensed Product will be free from infringement of any patent or other industrial or intellectual property
rights of any third party; or

 

		(b)	conferring by implication, estoppels or otherwise upon either party or its Affiliates any license
or other right under any patent or other industrial or intellectual property rights other than those rights expressly granted in
this Agreement; or

 

		(c)	imposing on any party any obligation to institute any suit or action for infringement of any of the
patents licensed under this Agreement or to defend any suit or action brought by a third party which challenges or concerns the
validity of any such patents.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	10

    	 

    

8.4ACCESS HEREBY WAIVES, RELEASES AND RENOUNCES ANY AND
ALL WARRANTIES, GUARANTEES, OBLIGATIONS, LIABILITIES, RIGHTS AND REMEMDIES, EXPRESS OR IMPLIED, ARISING BY LAW OR OTHERWISE, WITH
RESPECT TO THE USEFULNESS OR FREEDOM FROM DEFECTS OF THE LICENSED PRODUCTS, INCLUDING BUT NOT LIMITED TO: (A) ANY IMPLIED WARRANTY
OF MERCHANTABILITY OR FITNESS; (B) ANY IMPLIED WARRANTY ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE IN THE TRADE,
AND (C) ANY OBLIGATION, RIGHT, LIABILITY, CLAIM OR REMEDY FOR (1) LOSS OF USE, REVENUE OR PROFIT, OR ANY OTHER DAMAGES, (2) INFRINGEMENT
OF THIRD PARTY INTANGIBLE PROPERTY RIGHTS, AND (3) EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES.

 

ARTICLE 9.INDEMNITY

 

		9.1.	Access Indemnity. Subject to Section 8.4, Access agrees to defend, indemnify and hold Interleukin
harmless against all liability and costs (including reasonable attorneys’ fees) in connection with any third party claim
arising out of designing, using, importing, exporting, selling, offering to sell, licensing and/or distributing any product, method
or service utilizing the Interleukin Technology.

 

		9.2	Interleukin Indemnity. Interleukin agrees to defend, indemnify and hold harmless Access
and Access’s Affiliates, and their officers, directors, employees, and agents against all demands, liability and costs (including
attorneys’ fees) in connection with any third party claim arising out of or in connection with (a) Interleukin’s performance
of, or failure to perform, Interleukin’s obligations pursuant to this Agreement; or (b) any breach of any warranty, representation,
covenant, or agreement made by Interleukin to Access in this Agreement.

 

		9.3	Settlement. Before settling, compromising, or otherwise extinguishing any claim by a third
party (whether or not suit or any other type of dispute resolution procedure has been commenced) made against Interleukin (a “Settlement”),
Access must first obtain the written consent of Interleukin and Interleukin shall have discretion to withhold such consent if the
Settlement (a) is for or involves non-monetary consideration or non-monetary judicial relief, including, but not limited to, promises
by Interleukin to do or forbear from doing any act or the granting of equitable remedies, or (b) involves, requires, or implies
admissions of wrongful acts (whether civil or criminal) by Interleukin.

 

		9.4	Enforcement of Interleukin Technology. In the
event that either party becomes aware of a third party infringing Interleukin Technology by manufacture, use or sale of a Licensed
Product in the Field of Use and Territory, Interleukin shall have the right, but not the obligation, to bring an action against
such third party for infringement of Interleukin Technology. If Interleukin chooses not to bring an action against such third
party for infringement of Interleukin Technology then, upon the consent of Interleukin, Access shall have the right, but not the
obligation to take such action in Access’s name, and in the name of Interleukin. Interleukin agrees to cooperate with Access
in any such action at Access’s expense. Any funds recovered from such enforcement of Interleukin Technology shall be shared
proportionately between the parties in the same proportion that the parties shared the costs and expenses of enforcement hereunder.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	11

    	 

    

 

 

ARTICLE
10. GENERAL PROVISIONS

 

		10.1	Publicity. The parties agree that the parties shall issue a joint press release at a time determined
by Access, at its sole discretion, regarding this Agreement, and the content of such press release shall be jointly agreed to by
the parties. Neither party will otherwise disclose the terms of this Agreement except (a) as required by law or by the rules
and regulations of a stock exchange where securities of a party are traded, or (b) as a result of a binding order of a court or
governmental agency.

 

		10.2	Notices. All notices shall be in writing mailed via certified mail, return receipt requested, or delivered by a courier
service providing evidence of delivery, addressed as follows, or to such other address as may be designated from time to time:

 

	If to Interleukin:	If to Access:
	 	 
	135 Beaver Street	7575 Fulton Street East
	Waltham, MA 02452	Ada, MI USA 49355-0001
	 	 
	Attention: Chief Executive	Attention:  Vice President
	Officer	General Counsel
	 	Mail Stop 78-2G

 

		10.3	Governing Law. This Agreement shall be governed by and construed in accordance with the laws
of the State of Michigan, USA without regard to the application of principles of conflicts of law.

 

		10.4	Export Control. Neither party shall export, re-export, or transship any information or product
acquired or generated under this Agreement in violation of any applicable export control laws and regulations promulgated and administered
by the governments of the countries asserting jurisdiction over the parties or their applicable transactions.

 

		10.5	Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties
and their respective legal representatives, successors and permitted assigns.

 

		10.6	Headings. Article and section headings are inserted for convenience of reference only and do
not form a part of this Agreement.

 

		10.7	Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each
of which shall be deemed an original.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	12

    	 

    

		10.8	Amendment; Waiver. This Agreement may be amended, modified, superseded or canceled, and any
of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party or parties
waiving compliance. The delay or failure of any party at any time or times to require performance of any provisions shall in no
manner affect the rights at a later time to enforce the same. No waiver by any party of any condition or of the breach of any term
contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered
as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement.

 

		10.9	No Agency or Partnership. Nothing contained in this Agreement shall give either party the right
to bind the other, or be deemed to constitute the parties as agents for the other or as partners with each other or any third party.

 

		10.10	Assignment and Successors. This Agreement may not be assigned by either party without the written
consent of the other, which shall not be unreasonably withheld, except that each party may assign this Agreement and the rights,
obligations and interests of such party to any of its Affiliates or any purchaser of all or substantially all of its assets to
which this Agreement relates or to any successor entity resulting from any merger, reorganization, or consolidation of such party
with or into such entity, provided that such Affiliate or purchaser agrees to be bound by all of the terms and conditions of this
Agreement.

 

		10.11	Interpretation. The parties hereto acknowledge and agree that: (i) each party and its counsel
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction
to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this
Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all parties hereto and not in a
favor of or against any party, regardless of which party was generally responsible for the preparation of this Agreement.

 

		10.12	Integration; Severability. This Agreement is the sole agreement with respect to the subject
matter hereof and supersedes all other agreements and understandings between the parties with respect to same, and may not be modified
except in a writing signed by both parties; provided for avoidance of doubt that this Agreement does not supersede the Services
Agreement. The provisions of this Agreement shall be interpreted, if possible, so as to be valid, legal and enforceable. In the
event that any provision of this Agreement conflicts with the law under which this Agreement is to be construed or is otherwise
held to be invalid, illegal or unenforceable by a court or arbitration panel with jurisdiction over the parties to this Agreement,
such provision shall be deemed to be restated to reflect as nearly as possible the original intentions of the parties in accordance
with applicable law, and the remainder of this Agreement shall remain in full force and effect.

 

IN WITNESS WHEREOF,
the parties have caused this License Agreement to be executed by their duly authorized representatives.

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

 Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

    	13

    	 

    

  

	 	ACCESS BUSINESS GROUP
	 	INTERNATIONAL LLC
	 	 	 
	 	By	/s/ Jay G. Ertl
	 	 	 
	 	Printed Name	Jay G. Ertl
	 	 	 
	 	Title	Vice President – Product Demand
	 	 	 
	 	INTERLEUKIN GENETICS, INC.
	 	 	 
	 	By	/s/ Kenneth S. Kornman
	 	 	 
	 	Printed Name	Kenneth S. Kornman
	 	 	 
	 	Title	CEO
	 	 	 	 

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

 

    	14

    	 

    

Exhibit A

 

		1.	Eurasian Patent Organization; Serial No. [***] 

 

		2.	European Patent Convention; Serial No. [***]

 

		3.	European Patent Convention; Serial No. [***]

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the 

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

 

    	15

    	 

    

 

Exhibit B

[***]

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the 

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

 

    	16

    	 

    

 

SCHEDULE 3.1

 

ROYALTY REPORT FORM

 

REPORTING PERIOD: _____________________________________________________________

 

Individual to contact concerning this information:

 

Name: _______________ Phone # or email I.D.: ______________________________________

 

For each product / item subject to a royalty payment provision,
please provide the following information as applicable:

 

PRODUCT / ITEM: __________________________________________________________________

 

	
         

         

        Country
	
         

        Number of Units

 / Products Sold
	
         

         

        Royalty Rate
	
         

        Net Royalty

Payment Due

	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

  

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the 

Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment

pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

 

    	17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]